Aardvark Therapeutics, Inc. (NASDAQ: AARD) reported Q2 EPS of ($0.66), $0.04 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Aardvark Therapeutics, Inc. (AARD) click here.